Patent 9682975 was granted and assigned to Genzyme on June, 2017 by the United States Patent and Trademark Office.
The invention relates to a method of preparing inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.